Pluris­tem us­es the pre­clin­i­cal hype gam­bit to whip up a quick­ie stock gain

The view from End­points

In the world of drug de­vel­op­ment, mouse da­ta is a lit­tle like a bro­ken twig on a con­fus­ing trail. It­might tell you you’ve start­ed down the right path and it might lead ab­solute­ly nowhere. In the vast­ma­jor­i­ty of cas­es, you wind up in the wilder­ness — com­plete­ly lost and with noth­ing to show fory­our ef­fort.

Un­less you put out the right kind of press re­lease herald­ing your bro­ken twig as a clear sign of ma­jor progress. And if you’re a pub­lic com­pa­ny, you can al­so get an in­stan­ta­neous boost in your ail­ing stock price.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA